895TiPA phase I study of AMG 160, a half-life extended...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

895TiPA phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Tran, B, Kouros-Mehr, H, Fermin, A, Horvath, L, Roncolato, F, Rettig, M, Dorff, T, Tagawa, S T, Subudhi, S K, Antonarakis, E S, Armstrong, A J, Petrylak, D P, Fizazi, K, Salvati, M E, Scher, H I
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz248.052
Date:
October, 2019
File:
PDF, 74 KB
2019
Conversion to is in progress
Conversion to is failed